ADC Therapeutics

CEO Ameet Mallik (ex‑Novartis Oncology) has streamlined the portfolio and centered strategy on maximizing ZYNLONTA, securing additional financing and advancing confirmatory and combination trials. Execution discipline improved on expenses, but shareholder outcomes remain hostage to a single drug’s risk‑benefit and financing structure.

We see relevant experience and a pragmatic focus, but limited proof of durable value creation so far.